We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Mallinckrodt Up on New York's Support for Opioid Settlement
Read MoreHide Full Article
Shares of Mallinckrodt plc surged almost 40% on Wednesday amid sell-off in the broader S&P 500 Index, following the support of New York State Attorney General for the company’s previously announced proposed global opioid settlement. Including New York, 48 states and territories are now supporting the proposed settlement.
The motion to remove Mallinckrodt LLC and SpecGx LLC from the New York State trial related to opioid-abuse is currently pending before the Supreme Court of New York. However, the trial has been postponed indefinitely due to the coronavirus scare.
Mallinckrodt’s stock has slumped 86% in the past year compared with the industry’s decline of 10.7%.
Last month, Mallinckrodt and its specialty generics-focused subsidiaries Mallinckrodt LLC, SpecGx LLC, and certain other affiliates proposed an agreement in principle on the terms of a global settlement that would resolve all opioid-related claims against the company, Specialty Generics, and other subsidiaries.
The agreement in principle has been reached with a court-appointed plaintiff executive committee, representing the interests of thousands of plaintiffs in the opioid multidistrict litigation. Mallinckrodt expects that Specialty Generics, which manufactures certain generic opioid products, among other products, will file voluntary petitions under Chapter 11 of the U.S. Bankruptcy Code in the coming months. The settlement terms include structured payments of $1.3 billion over eight years and warrants for 19.99% of the company's outstanding shares. Additional $300 million will be paid to the plaintiffs upon Specialty Generics’ emergence from bankruptcy.
We note that Mallinckrodt has entered into a number of settlement agreements related to opioid abuse in 2019. A global settlement of the opioid litigation will remove a major overhang on the stock.
Apart from Mallinckrodt, many pharma companies like J&J (JNJ - Free Report) Endo International and Teva Pharma (TEVA - Free Report) are embroiled in multiple opioid litigations filed by several states, counties and political subdivisions in the United States regarding the abuse of opioid-based drugs. The industry players have been accused of faulty marketing practices, which downplayed addiction risks from these drugs and spurred their consumption instead.
Per the National Institute of Drug Abuse, opioid overdose claimed lives of 47,000 Americans in 2017. Moreover, prescription opioid misuse alone creates a total economic burden of $78.5 billion every year. In the past two decades, 400,000 deaths occurred due to opioid-based drug abuse, per the estimate of Centers for Disease Control and Prevention.
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
Mallinckrodt Up on New York's Support for Opioid Settlement
Shares of Mallinckrodt plc surged almost 40% on Wednesday amid sell-off in the broader S&P 500 Index, following the support of New York State Attorney General for the company’s previously announced proposed global opioid settlement. Including New York, 48 states and territories are now supporting the proposed settlement.
The motion to remove Mallinckrodt LLC and SpecGx LLC from the New York State trial related to opioid-abuse is currently pending before the Supreme Court of New York. However, the trial has been postponed indefinitely due to the coronavirus scare.
Mallinckrodt’s stock has slumped 86% in the past year compared with the industry’s decline of 10.7%.
Last month, Mallinckrodt and its specialty generics-focused subsidiaries Mallinckrodt LLC, SpecGx LLC, and certain other affiliates proposed an agreement in principle on the terms of a global settlement that would resolve all opioid-related claims against the company, Specialty Generics, and other subsidiaries.
The agreement in principle has been reached with a court-appointed plaintiff executive committee, representing the interests of thousands of plaintiffs in the opioid multidistrict litigation. Mallinckrodt expects that Specialty Generics, which manufactures certain generic opioid products, among other products, will file voluntary petitions under Chapter 11 of the U.S. Bankruptcy Code in the coming months. The settlement terms include structured payments of $1.3 billion over eight years and warrants for 19.99% of the company's outstanding shares. Additional $300 million will be paid to the plaintiffs upon Specialty Generics’ emergence from bankruptcy.
We note that Mallinckrodt has entered into a number of settlement agreements related to opioid abuse in 2019. A global settlement of the opioid litigation will remove a major overhang on the stock.
Apart from Mallinckrodt, many pharma companies like J&J (JNJ - Free Report) Endo International and Teva Pharma (TEVA - Free Report) are embroiled in multiple opioid litigations filed by several states, counties and political subdivisions in the United States regarding the abuse of opioid-based drugs. The industry players have been accused of faulty marketing practices, which downplayed addiction risks from these drugs and spurred their consumption instead.
Per the National Institute of Drug Abuse, opioid overdose claimed lives of 47,000 Americans in 2017. Moreover, prescription opioid misuse alone creates a total economic burden of $78.5 billion every year. In the past two decades, 400,000 deaths occurred due to opioid-based drug abuse, per the estimate of Centers for Disease Control and Prevention.
Mallinckrodt public limited company Price
Mallinckrodt public limited company price | Mallinckrodt public limited company Quote
Zacks Rank
Mallinckrodt currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>